DIRS.INFO The most relevant business & tech news

☆ A new blood test can spot signs of colon cancer in your annual blood draw
▼ + stars: | 2024-07-30 | by ( ) www.businessinsider.com time to read: +3 min

The organization also estimates more than 150,000 new cases of colorectal cancer will be diagnosed this year. Colon cancer is highly treatable when caught before it spreads to other areas of the body, according to the National Cancer Institute. However, the rate of diagnoses and deaths from colon cancer has been steadily going up in people under 45, alarming doctors and researchers. AdvertisementWe don't fully understand why younger people are getting colon cancer and dying from it more frequently. Risk factors for colorectal cancer include genetics, a family history of colon cancer or colorectal polyps, and other health conditions such as inflammatory bowel disease.

Persons: —, it's, David Chung, Guardant, Chung, Colon Organizations: Service, Drug Administration, Guardant Health, Business, Harvard Medical, FDA, American Cancer Society, National Cancer Institute Locations: Colon

☆ F.D.A. Approves Blood Test for Colon Cancer Detection
▼ + stars: | 2024-07-29 | by ( Gina Kolata | ) www.nytimes.com time to read: +1 min

The Food and Drug Administration on Monday approved a new screening test for colorectal cancer. For many people, a routine blood test is easier to get than a colonoscopy or a fecal sample test. But the blood test, made by Guardant Health of Palo Alto, Calif., comes with a limitation. It is approved for people aged 45 and over who are at average risk for colon cancer. As many as 53,000 Americans are expected to die from colorectal cancer this year.

Persons: Guardant, Matt Burns Organizations: Drug Administration, Guardant Health, Palo Locations: Palo Alto, Calif, United States

☆ Stocks making the biggest moves premarket: Ross Stores, Intuit, Workday, Guardant Health and more
▼ + stars: | 2024-05-24 | by ( Brian Evans | ) www.cnbc.com time to read: +2 min

Check out the companies making headlines in premarket trading: Intuit — The TurboTax parent company slipped nearly 6% after issuing weaker-than-expected fiscal fourth-quarter guidance . Intuit forecast adjusted earnings of $1.80 per share to $1.85 per share, while analysts surveyed by FactSet expected $1.92. Ross Stores — The discount apparel retailer stock added more than 7% on the heels of an earnings beat. Workday forecast subscription revenue of $1.895 billion, while the consensus forecast called for $1.9 billion, according to StreetAccount. Analysts surveyed by LSEG were looking for $2.89 in earnings per share on $888 million of revenue.

Persons: Cash, —, Jesse Pound Organizations: Intuit, Ross Stores, LSEG, Nvidia, U.S . Food, Drug Administration Locations: U.S

☆ Stocks making the biggest moves midday: Workday, Lucid, Toast, Deckers and more
▼ + stars: | 2024-05-24 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Ross Stores posted earnings of $1.46 per share on $4.86 billion in revenue. Revenue came out at $2.77 billion, slightly higher than analysts' forecast of $2.72 billion. Intuit forecast adjusted earnings of $1.80 per share to $1.85 per share, while analysts polled by FactSet expected $1.92 per share. Toast — Shares of the financial tech company, which specializes in point-of-sale products for restaurants, gained nearly 1%. Workday forecast subscription revenue of $1.895 billion, while the consensus forecast called for $1.9 billion, per StreetAccount.

Persons: Booz Allen Hamilton, Booz Allen, Robinhood, FactSet, Moshe Katri, Katri, LSEG, —, Jesse Pound, Tanaya Macheel, Alex Harring, Samantha Subin Organizations: Ross Stores, Ross, LSEG, Revenue, U.S . Securities, Exchange Commission, Intuit —, Intuit, Food and Drug Administration

☆ Earnings will drive the market next week — what we expect from 2 portfolio stocks
▼ + stars: | 2024-05-04 | by ( Zev Fima | ) www.cnbc.com time to read: +10 min

With the Fed, Apple earnings and the jobs report passing with flying colors this week, the runway to more gains looks a lot less cluttered. This past week was chock full of Club earnings: 12 portfolio companies, including Apple , delivered results. Analysts expect Wynn's earnings per share of $1.27 versus 29 cents a year ago when China was not fully back from Covid. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Jerome Powell, we're, Jim Cramer, Jim, Apple, Eli Lilly, Estee Lauder, Stanley Black, Decker, Bausch, FactSet, It's, Bob Iger, Iger, Nelson Peltz, We're, Krystal, Berkshire Hathaway, Tyson, Jones Lang, Walt, Ferrari N.V, WK Kellogg, Wynn, Vishay, CRON, MARA, RICK, Ginkgo, Jim Cramer's, David Paul Morris Organizations: Federal Reserve, Apple, GE Healthcare, DuPont, Linde, Bausch Health, Coterra Energy, Club, Disney, Wynn Resorts, CNBC, Revenue, Vegas Sands, Cotai, Boston, Airlines, Krystal Biotech, Alpha Metallurgical Resources, Axsome Therapeutics, Tyson Foods, TSN, Bowlero Corp, CNA Financial Corp, CNA, Jones Lang LaSalle Incorporated, Technologies, Realty Income Corp, Lab, Teradata Corp, Technology, FMC Corporation, FMC, Paymentus Holdings, Shockwave, Vertex Pharmaceuticals, Goodyear Tire & Rubber Company, Simon Property Group, Sterling Construction Company, Apple Hospitality, Boise Cascade Corporation, BellRing Brands, Coty, COTY, Fidelity National Information Services Inc, Vornado Realty, Walt Disney Co, Holdings, Madrigal Pharmaceuticals, Nikola Corporation, BP, Rockwell Automation, MarketAxess Holdings, Jumia Technologies, GEO Group, Builders FirstSource Inc, Duke Energy Corp, WYNN, Rivian Automotive, Arista Networks, Occidental Petroleum Corp, Astera Labs, Bros, Flywire Corporation, B2Gold Corp, Kinross Gold Corp, Virgin Galactic Holdings, iRobot Corp, Electronic Arts Inc, McKesson Corp, ACM Research, Avadel Pharmaceuticals, Toyota Motor Corp, Emerson Electric Co, Perion, Editas, Brink's Company, Sinclair Corporation, New Fortress Energy, Starwood Property Trust, Animal Health, ELAN, Farms, IM Cannabis Corp, Fox Corporation, Formula One, Icahn Enterprises, Teva Pharmaceutical Industries, Arm Holdings plc, ARM, AMC Entertainment Holdings, Trade, AppLovin Corporation, Sciences Corp, SolarEdge Technologies, Roblox Corporation, GigaCloud Technology Inc, Warner Bros ., Properties Trust, Growers, Constellation Energy Group, Cronos, Fiverr, Solar Inc, EPAM Systems, Cedar Fair Entertainment, Digital Holdings, RCI Hospitality Holdings, Akamai Technologies, Semiconductor, Insulet Corp, NuScale Power Corporation, Ginkgo Bioworks Holdings, Bloom Energy Corporation, Construction, AMC Networks, CRH Public Ltd . Company, Jim Cramer's Charitable, Allen, Co . Media, Technology Conference, Bloomberg, Getty Locations: China, Eaton, Amazon, Covid, Macao, Vegas, Sun Valley , Idaho

☆ Cramer's Lightning Round: 'I remain a buyer' of SoFi
▼ + stars: | 2023-11-27 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

Stock Chart Icon Stock chart icon Barrick Gold's year-to-date stock performance. Stock Chart Icon Stock chart icon Generac's year-to-date stock performance. Stock Chart Icon Stock chart icon Golden Ocean's year-to-date stock performance. Stock Chart Icon Stock chart icon Guardant Health's year-to-date stock performance. Stock Chart Icon Stock chart icon Walgreens' year-to-date stock performance.

Persons: Guardant Organizations: Barrick, Guardant, Walgreens

☆ Lightning Round: Stay long SoFi, says Jim Cramer
▼ + stars: | 2023-11-27 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailLightning Round: Stay long SoFi, says Jim Cramer'Mad Money' host Jim Cramer weighs in on stock including: Barrick Gold, Generac, Golden Ocean, Guardant Health, SoFi and Walgreens.

Persons: Jim Cramer, Barrick Organizations: SoFi, Walgreens

☆ Here are Monday's biggest analyst calls: Apple, Amazon, Oracle, Eli Lilly, Airbnb, Meta, Southwest & more
▼ + stars: | 2023-11-13 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Jefferies initiates PepsiCo as buy Jefferies called PepsiCo a defensive stock. " Jefferies initiates Procter & Gamble as buy Jefferies said in its initiation of the stock that it's a top and bottom line growth leader. Jefferies initiates Colgate-Palmolive as buy Jefferies said it sees a "reinvigorated" brand lineup for Colgate. Citi reiterates Amazon and Meta as buy Citi said it's bullish on the partnership between Amazon and Meta. Citi reiterates Eli Lilly as buy Citi said it's standing by its buy rating on the stock.

Persons: Piper Sandler, Stifel, CrowdStrike, KBW, it's, Bernstein, buybacks, Airbnb, BTIG, Raymond James, Natera, Hewlett Packard, Jefferies, Colgate, Morgan Stanley, Edward Jones, Olin, it's bullish, Truist, Citi, Eli Lilly, Lilly, Melius Organizations: UBS, Barclays, Apple, Piper, Capital Holdings, Guardant, Citi, Hewlett, PepsiCo, Pepsi, Procter, Gamble, G, Constellation Brands, Constellation, Colgate, Palmolive, Mirum Pharmaceuticals, Oracle, North America, Amazon, Social Commerce, ~$

☆ Piper Sandler upgrades Guardant Health, says shares can rally more than 55%
▼ + stars: | 2023-09-27 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Piper Sandler is bullish on oncology company Guardant Health for the long term. Analyst David Westenberg upgraded Guardant Health to overweight from neutral and maintained his $40 price target, which implies 55% upside for the stock from Tuesday's close. The company owns the first FDA-approved comprehensive liquid biopsy treatment for all advanced solid tumors. Shares of Guardant Health added about 6%. Guardant Health received approval from the U.S. Food and Drug Administration in January for its Guardant360 liquid biopsy test, which helps identify advanced or metastatic breast cancer patients with ESR1 mutations.

Persons: Piper Sandler, David Westenberg, Westenberg, Guardant Organizations: Guardant Health, Guardant, FDA, U.S . Food, Drug Administration Locations: U.S, MRD, Guardant

☆ Stocks making the biggest moves midday: Costco, Paramount, MillerKnoll, ChargePoint and more
▼ + stars: | 2023-09-27 | by ( Samantha Subin | ) www.cnbc.com time to read: +3 min

Media stocks — A handful of media and studio stocks rose Wednesday after the nearly 150-day writer strike ended. ChargePoint , Blink Charging — Shares of ChargePoint and Blink Charging gained 4.1% and 5.5%, respectively after UBS initiated coverage of the electric charging stocks with buy ratings. XPO — Shares added roughly 2% after XPO stock was upgraded to outperform from Evercore ISI, with analyst Jonathan Chappell highlighting margin growth potential and stronger pricing power. Mattel — Shares of the toymaker rose more than 4% after Morgan Stanley initiated coverage of Mattel with an overweight rating. AAR Corp — Shares of the aircraft services company rose 2.3% on the back of its quarterly earnings report.

Persons: MillerKnoll, XPO, Jonathan Chappell, Morgan Stanley, Levi Strauss, TD Cowen, Levi's, Piper Sandler, Kosmos, — CNBC's Brian Evans, Alex Harring, Jesse Pound, Hakyung Kim Organizations: Media, Warner Bros . Discovery, Paramount Global, Comcast, Disney, Netflix, UBS, Costco —, Costco, Evercore ISI, Mattel —, Mattel, Federal Trade Commission, AAR, Kosmos Energy, Bank of America

☆ Is ChatGPT the tip of the iceberg? Analysts reveal potential A.I. uses — and the stocks to play it
▼ + stars: | 2023-03-01 | by ( Zavier Ong | ) www.cnbc.com time to read: +3 min

ChatGPT is considered by far the most successful generative AI tool to date. But while ChatGPT is undoubtedly the talk of the town, HSBC believes it could just be the tip of the generative AI iceberg. However, there is the potential for Generative AI to have a significant impact on several sectors of the economy," the bank said. How to play it Morgan Stanley has named a raft of global stocks to play generative AI. Medical diagnostics Meanwhile, Canaccord Genuity in a Feb. 20 note highlighted the implications of AI on the medical diagnostics sector.

☆ This little-known health stock that uses A.I. can rally more than 120%, Canaccord Genuity says
▼ + stars: | 2023-02-22 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Oncology stock Guardant Health could be a big winner in the ChatGPT-driven artificial intelligence frenzy, according to Canaccord Genuity. Canaccord anticipates Guardant Health will see some upside, boosted by its AI-related suite of technology the company announced in January . ChatGPT also could enable 24-hour/7-day access to healthcare services," Mikson wrote. Guardant Health last month announced the launch of its Guardant Galaxy platform, which includes technologies that will aid in the company's tests and enable biomarker and drug discovery. The first application in the company's product suite is an AI-backed digital-pathology platform developed by Lunit, a South Korea-based company.

☆ Stocks making the biggest moves premarket: Accenture, Winnebago, Maxar Technologies and more
▼ + stars: | 2022-12-16 | by ( Peter Schacknow | ) www.cnbc.com time to read: +2 min

Accenture issued a revenue range for the current quarter whose midpoint is below current consensus and said the stronger U.S. dollar will impact its fiscal 2023 results by 5%. Maxar Technologies (MAXR) – The satellite owner and operator's shares more than doubled in the premarket after it agreed to be acquired by private equity firm Advent International for $53 per share. Guardant Health (GH) – Guardant shares plunged 33.4% in the premarket following trial results for its DNA blood test for colorectal cancers. Adobe also issued upbeat current quarter guidance. U.S. Steel (X) – U.S. Steel issued better-than-expected current quarter guidance and said commercial demand for steel is on the upswing in the U.S.

☆ Stocks making the biggest moves midday: Meta, Maxar Technologies, Ford, Goldman Sachs and more
▼ + stars: | 2022-12-16 | by ( Samantha Subin | ) www.cnbc.com time to read: +3 min

Goldman Sachs — Goldman Sachs shares slumped 1% amid news that the Wall Street firm will cut up to 8% of its workforce. The layoffs are slated to come in January and hit all areas of the Wall Street firm, CNBC reported, citing people familiar with the matter. The Wall Street firm cited recent underperformance in net adds as well as growing macro headwinds to advertising revenues. Lincoln National — Shares dropped more than 4% after Lincoln National was downgraded to underperform from hold at Jefferies, according to StreetAccount. JD.com and Alibaba shares rose more than 1% .

ETMeta up on J.P. Morgan rating upgradeDigital World Acquisition down on CFO exitFutures down: Dow 1.16%, S&P 1.05%, Nasdaq 0.60%Dec 16 (Reuters) - Wall Street's main stock indexes were set to extend losses on Friday as fears of a looming recession, sparked by the Federal Reserve's relentless battle against inflation, hammered sentiment. The Bank of England and the European Central Bank were the latest ones to indicate an extended rate-hike cycle on Thursday. The simultaneous expiration of stock options, stock index futures and index options contracts later in the day, known as triple witching, could cause volatility through the trading session. ET, Dow e-minis were down 384 points, or 1.16%, S&P 500 e-minis were down 41.25 points, or 1.05%, and Nasdaq 100 e-minis were down 68.5 points, or 0.6%. Reporting by Shubham Batra, Ankika Biswas and Johann M Cherian in Bengaluru; Editing by Anil D'SilvaOur Standards: The Thomson Reuters Trust Principles.

[1/2] A trader works on the trading floor at the New York Stock Exchange (NYSE) in New York City, U.S., December 14, 2022. Adding to angst, New York Fed President John Williams said it remains possible the U.S. central bank raises rates more than it expects next year. The policymaker added that he does not anticipate a recession from the Fed's aggressive tightening. The simultaneous expiration of stock options, stock index futures and index options contracts later in the day, known as triple witching, could cause volatility through the trading session. The S&P index recorded no new 52-week highs and 15 new lows, while the Nasdaq recorded 29 new highs and 267 new lows.

"The jury is still out," on which technology will dominate, said Dr. Sadik Esener, director of the Cancer Early Detection Advanced Research Center at the OHSU Knight Cancer Institute in Portland, Oregon. He added it could take as long as 20 years to show that an early cancer detection test saved lives. If proven to work, early cancer detection tests could help doctors identify cancer risk in patients long before symptoms or other indicators develop. DIFFERENT APPROACHESSeveral of the leading contenders take vastly different approaches to cancer detection and it is not yet clear which methods will prove most useful or when. Some are working on blood tests to detect different markers of early cancer, including proteins.

☆ Guardant DNA blood test finds 83% of colorectal cancers in trial, shares fall 39%
▼ + stars: | 2022-12-15 | by ( Deena Beasley | ) www.reuters.com time to read: +2 min

Cologuard, a stool-based DNA test, identifies 92% of colorectal cancers and 42% of pre-cancerous polyps, according to data from Exact Sciences (EXAS.O), which markets the test. Guardant said that a subsequent colonoscopy ruled out colon cancer in 10% of people who tested positive with its DNA blood test. "This is a huge unmet clinical need," Talasaz said of a blood test for detecting colon cancer. "There are still 50 million people out there who are not complying with colorectal cancer screening." Guardant is currently enrolling patients in a different trial of its DNA blood test for detecting lung cancer, Talasaz said.

☆ A Silicon Valley biotech just showed a simple blood test can detect a hidden and deadly type of cancer. But the results fell short of investors' hopes.
▼ + stars: | 2022-12-15 | by ( Leah Rosenbaum | ) www.businessinsider.com time to read: +7 min

Guardant Health said that its blood test to screen for cancer caught 83% of colorectal cancer cases. On Thursday, Silicon Valley-based biotech Guardant Health announced that its blood-based cancer screening test correctly caught colorectal cancer cases in 83% of people who had the disease. The company already has several products on the market, including Guardant360CDx, an FDA-approved blood test to test cancer genomic markers that could help show what treatments the cancers are susceptible to. Colonoscopies are still the gold standard of colorectal cancer screening, despite involving sedation and hours of unpleasant physical preparation. And while colorectal cancer is the first cancer that is being studied for a blood-based screening, it certainly won't be the last.

Search resuls for: "Guardant Health"

19 mentions found